Stephen Kraus

Stephen Kraus is a Vice President in the Wellesley Hills office, where he works with Chris Gabrieli covering the healthcare sector, which includes therapeutics, medical device, healthcare service, and healthcare IT companies.  Steve is actively involved with BVP's investments in Affymax (NASDAQ:AFFY), Oxagen, Aveo (NASDAQ:AVEO), Acceleron, Transave, Cerulean, Stromedix, Acorn Cardiovascular, Proteon, and On-Q-ity. He served on the boards of Sirtris (NASDAQ:SIRT) until its IPO, and of Restore (NASDAQ:REST) until its acquisition by Medtronic (NYSE:MDT) in July 2008. Steve currently sits on the boards of Transave and On-Q-ity.

Prior to joining Bessemer, Steve was a Director at the Ironwood Equity Fund, a growth-stage private equity firm, and a management consultant at Bain & Company. In 2002, he served as Speechwriter and Operations Director for the Democratic nominee for Governor of Massachusetts.

Steve graduated summa cum laude from Yale University and earned his MBA from Harvard Business School, where he was a Baker Scholar. He serves on the boards of City on a Hill Public Charter School and Interise.

  
Acceleron Pharma is a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle.
In 2005, BVP invested in Affymax, a drug discovery and product development company that is creating novel peptide drugs for the treatment of serious and life-threatening conditions related to kidney disease and cancer. Eighteen months later, the company went public (NASDAQ:AFFY).
Alnara develops non-systemic protein therapeutics to treat metabolic and inflammatory diseases.
Aveo Pharmaceuticals discovers and develops novel cancer therapeutics.
Cerulean uses nanotechnology to achieve dramatic improvements in the efficacy and safety profile of new and existing drugs.
On-Q-ity is an innovative diagnostic company that provides physicians with the tools they need to make the best decision when treating individual cancer patients. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream.
Oxagen is developing an improved treatment for asthma.
Proteon Therapeutics is a biopharmaceutical company using tissue remodeling techniques to develop novel pharmaceuticals that address the medical needs of patients with renal and vascular diseases.
Stromedix is a biotechnology company committed to developing innovative therapies to treat fibrosis.
A biopharmaceutical company, Transave uses proprietary technology to develop innovative, inhaled pharmaceuticals for the treatment of serious lung diseases.